Rani Therapeutics Holdings Stock Current Asset
| RANI Stock | USD 2.02 0.03 1.51% |
Rani Therapeutics Holdings fundamentals help investors to digest information that contributes to Rani Therapeutics' financial success or failures. It also enables traders to predict the movement of Rani Stock. The fundamental analysis module provides a way to measure Rani Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rani Therapeutics stock.
The Rani Therapeutics' current Total Current Assets is estimated to increase to about 79.9 M, while Non Current Assets Total are projected to decrease to under 6.5 M. Rani | Current Asset |
Rani Therapeutics Holdings Company Current Asset Analysis
Rani Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Rani Current Asset Historical Pattern
Today, most investors in Rani Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Rani Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Rani Therapeutics current asset as a starting point in their analysis.
Rani Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Rani Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Rani Therapeutics Holdings has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Rani Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rani Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics of similar companies.Rani Therapeutics is currently under evaluation in current asset category among its peers.
Rani Fundamentals
| Return On Equity | -2.25 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 69.62 M | ||||
| Shares Outstanding | 33.31 M | ||||
| Shares Owned By Insiders | 30.61 % | ||||
| Shares Owned By Institutions | 19.58 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Book | 21.25 X | ||||
| Price To Sales | 313.17 X | ||||
| Gross Profit | 2.72 M | ||||
| EBITDA | (65.28 M) | ||||
| Net Income | (33.97 M) | ||||
| Cash And Equivalents | 98.17 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 30.1 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 14.02 X | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (51.24 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Price To Earnings To Growth | 0.68 X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 140 | ||||
| Beta | 0.11 | ||||
| Market Capitalization | 116.52 M | ||||
| Total Asset | 57.92 M | ||||
| Retained Earnings | (72.89 M) | ||||
| Working Capital | 42.86 M | ||||
| Net Asset | 57.92 M |
About Rani Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rani Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:Check out Rani Therapeutics Piotroski F Score and Rani Therapeutics Altman Z Score analysis. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.57) | Return On Equity (2.25) |
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.